Disc Medicine (IRON) posted strong APOLLO Phase 3 bitopertin results in EPP/XLP and plans an end-2026 NDA resubmission.

The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...

Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of conc ...

Inventus Mining Corp. (TSXV: IVS) ('Inventus” or the 'Company”) is pleased to announce that Phase 3 drilling is underway at its 100%-owned Pardo 'River of Gold” Project near Sudbury, Ontario. The ...

Lindt & Sprüngli announced today that Group CEO Adalbert Lechner will leave the company. The Board of Directors has initiated ...

HAL is reportedly preparing an expanded CATS line-up for Aero India 2027, featuring a larger Warrior Phase-II, an ...

The proprietary trading firm previously operating as Hantec Trader has today begun operating under the name RZR Funded, ...

Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and ...

AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...

The novel phosphodiesterase 9 inhibitor tovinontrine failed to improve NT-proBNP in two parallel phase II trials, albeit with some signal for a benefit from a low dose.

Construction of the Sabah Pan Borneo Highway Phase 1A is nearly seven percentage points behind schedule, with contractor ...

From exchange competition to confidential filings, Hong Kong is reshaping market access, and companies must reassess timing, ...